Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial. Issue 12 (8th December 2019)

• Record Type: Journal Article
• Authors: de Boer, Nadine Leonie; Brandt-Kerkhof, Alexandra R M; Madsen, Eva V E; Diepeveen, Marjolein; van Meerten, Esther; van Eerden, Ruben A G; de Man, Femke M; Bouamar, Rachida; Koolen, Stijn L W; de Hingh, Ignace H J T; Bakkers, Checca; Rovers, Koen P; Creemers, Geert-Jan M; Deenen, Maarten J; Kranenburg, Onno W; Constantinides, Alexander; Mathijssen, Ron H J; Verhoef, Cornelis; Burger, Jacobus W A
• Is Part Of: BMJ open. Volume 9:Issue 12(2019)
• Publication Date: 2019-12-08
• Subjects: colorectal cancer -- peritoneal metastases -- intraperitoneal chemotherapy -- systemic chemotherapy -- palliative treatment -- dose-escalation study; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-034508
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has become standard of care for patients with peritoneal metastases of colorectal origin with a low/moderate abdominal disease load. In case of a peritoneal cancer index (PCI) score >20, CRS-HIPEC is not considered to be beneficial. Patients with a PCI >20 are currently offered palliative systemic chemotherapy. Previous studies have shown that systemic chemotherapy is less effective against peritoneal metastases than it is against haematogenous spread of colorectal cancer. It is suggested that patients with peritoneal metastases may benefit from the addition of intraperitoneal chemotherapy to systemic chemotherapy. Aim of this study is to establish the maximum tolerated dose of intraperitoneal irinotecan, added to standard of care systemic therapy for colorectal cancer. Secondary endpoints are to determine the safety and feasibility of this treatment and to establish the pharmacokinetic profile of intraperitoneally administered irinotecan. Methods and analysis: This phase I, '3+3' dose-escalation, study is performed in two Dutch tertiary referral centres. The study population consists of adult patients with extensive peritoneal metastases of colorectal origin who have a good performance status and no extra-abdominal metastases. According to standard work-up for CRS-HIPEC, patients will undergo a diagnostic laparoscopy to score the PCI. In case of a PCI >20, a peritoneal access port will be placed in the abdomen of the patient. Through this port we will administer intraperitoneal irinotecan, in combination with standard systemic treatment consisting of 5-fluorouracil/leucovorin with oxaliplatin and the targeted agent bevacizumab. Therapy consists of a maximum of 12 cycles 2-weekly. Ethics and dissemination: This study protocol is approved by a research medical ethics committee (Rotterdam, Netherlands) and the Dutch Competent Authority (CCMO, The Hague, Netherlands). The results of this trial will be submitted for publication in a peer-reviewed scientific journal. Trail registration number: NL6988 and NL2018-000479-33; Pre-results.